NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.5919 -0.03 (-4.82 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$0.5919
Today's Range$0.5704 - $0.6245
52-Week Range$0.53 - $2.38
Volume323,543 shs
Average Volume315,361 shs
Market Capitalization$42.05 million
P/E Ratio-0.47
Dividend YieldN/A
Beta0.82
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
Previous Symbol
CUSIPN/A
Phone617-349-1971

Debt

Debt-to-Equity RatioN/A
Current Ratio10.81
Quick Ratio10.81

Price-To-Earnings

Trailing P/E Ratio-0.47
Forward P/E Ratio-1.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales84.10
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.51 per share
Price / Book1.16

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-27,360,000.00
Net MarginsN/A
Return on Equity-91.16%
Return on Assets-76.86%

Miscellaneous

Employees36
Outstanding Shares71,040,000
Market Cap$42.05 million
OptionableNot Optionable

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) released its earnings results on Tuesday, November, 13th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.08. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

3 Wall Street analysts have issued twelve-month price targets for Catabasis Pharmaceuticals' shares. Their predictions range from $1.50 to $7.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $3.8333 in the next year. This suggests a possible upside of 547.6% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.

What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

News stories about CATB stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of Catabasis Pharmaceuticals' key competitors?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 50)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 57)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 61)
  • Mr. Noah Clauser, VP of Fin. & Controller
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 53)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an IPO on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc (3.51%), Stonepine Capital Management LLC (3.05%), Oppenheimer & Co. Inc. (0.72%), Renaissance Technologies LLC (0.64%) and BlackRock Inc. (0.24%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Which institutional investors are selling Catabasis Pharmaceuticals stock?

CATB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Stonepine Capital Management LLC and Vanguard Group Inc. View Insider Buying and Selling for Catabasis Pharmaceuticals.

Which institutional investors are buying Catabasis Pharmaceuticals stock?

CATB stock was purchased by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc. and BlackRock Inc.. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $0.5919.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $42.05 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-27,360,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Catabasis Pharmaceuticals employs 36 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is http://www.catabasis.com.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall SquareBldg. 1400E SuiteB14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  454
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel